Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001144204-17-012932
Filing Date
2017-03-06
Accepted
2017-03-06 16:01:32
Documents
3
Group Members
DAVID E. SHAW

Document Format Files

Seq Description Document Type Size
1 SC 13G v461182_sc13g.htm SC 13G 43946
2 EXHIBIT 1 v461182_ex1.htm EX-99.1 6248
3 EXHIBIT 2 v461182_ex2.htm EX-99.2 4019
  Complete submission text file 0001144204-17-012932.txt   55896
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-44055 | Film No.: 17667841
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036
Business Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036 2124780000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G